fda warning letters glp-1 september 2025 news Drug Recalls and Warnings: Illegal Sales and Misleading Marketing by Novo Nordisk and Eli Lilly FDA and Novo Nordisk Warned

An LDI Fellow and Chronic Pain Researcher Call on Health Plans To Lower Barriers to Physical Therapy, Acupuncture, and Interdisciplinary Pain Care Chart of the Day: Researchers Urge Easier Renewals and Better Support To Prevent Gaps in Care While They Wait for Medicare, People Approved for Social Security Disability Die at Higher Rates Compared to the General Public

ScienceDirect Al Qassab M, et al

Alo VIP Private Community to be a sanctuary away from social media noise

The bridge program is an 18-month demonstration intended to give CMS data on whether expanded GLP-1 coverage for chronic weight management makes sense long-term

If you have further questions, especially after more information is available, we encourage you to call your local State Health Insurance Assistance Program (whose number can be found at or Medicare Rights free, national helpline 800-333-4114

Fukuda G, Yoshida T, Hirayama A, Umezawa Y, Takemoto M (2019) Dulaglutide-related bullous pemphigoid in a patient with type 2 diabetes: a case report